Ajai Chari, MD, discusses the rationale for using combination therapy in patients with multiple myeloma.
Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, discusses the rationale for using combination therapy in patients with multiple myeloma.
Historically, Chari says that every drug in the treatment landscape has only worked for a short period of time in these patients. Because of this, the agents are combined to increase both response and duration of response, while also decreasing resistance.
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More